SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Romeo who wrote (5599)10/27/1998 5:29:00 AM
From: nord  Read Replies (1) of 6136
 
The results of the phase 2 trial with Haart and Remune. As I suggested previously the upfront HAART therapy is IMO not optimal therapy. The addition of Remune to one arm is suggestive that the drug is active. The problems the numbers are small and the upfront therapy is not the most potent combination. The question if Remune is capable of boosting specific T cell responses seeems based on early small numbers, none the less is encouraging. As an infectious disease doctor the problem we face now is durability. I have been amazed at the clinical and [lab marker response viral load CD4 ct] that we are capable of acheiving in both the naaive and heavily pretreated patients. My concern now is even with good patient compliance given the viral replication and high mutation rate of the virus that even HAART will not contol the virus with time. If in fact the addition of Remune to therapy is able to boost the patients immune response then the prospects for extended durability of existing anti-virals may well be prolonged. While this is a novel approach to stimulate the patients immune system it is so far promising. Time will tell. As the weeks go by the data even in small numbers becomes more meaningful. Bottom line too early to break out the champagne but if the trend hold Remune may make Viracept success seem trivial. More hope for pwa
Regards,
Norden
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News